Farydak®(panobinostat)

Farydak®(panobinostat)

In March 2019 Secura Bio acquired the global rights of Farydak from Novartis, and announced that Inceptua is appointed as distributor for Farydak in the Nordic region.

Farydak (panobinostat) is a prescription oral medication used in combination with proteasome inhibitors and corticosteroids to treat patients with relapsed or refractory multiple myeloma who have received prior treatments.

Please always consult local prescribing information and labelling text before use.

For more information about Farydak please refer to the prescribing information: European Medicines Agency.

Medical information

If you would like to speak to a medical representative, please use the relevant local/regional phone number below or contact:

info@securabio.com

  • Denmark: +45 89 88 16 39
  • Finland: +358 9 42452155
  • Sweden: +46 8 446 826 88
  • Iceland: +354 519 3659
  • Norway: 800 24 989 (toll free)

Safety and adverse events

Patient safety is a key priority for us. For any suspected adverse drug reactions associated with Farydak supplied by Inceptua, please contact:

securabio@parexcel.com

Telephone: +1-978-435-6968 / Fax: +1-858-925-6211